Antiangiogenic effects of zoledronate on cancer neovasculature

Future Oncology

Volumn 7, Issue 11, 2011, Pages 1325-1333

  Metcalf, Stephen ^a   Pandha, Hardev S ^a   Morgan, Richard ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

angiogenesis; cancer; neovasculature; zoledronate

Indexed keywords

AFLIBERCEPT; ALPHA INTERFERON; BETA INTERFERON; BEVACIZUMAB; DOCETAXEL; ENDOSTATIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GEMCITABINE; INTERLEUKIN 12; INTERLEUKIN 18; MARIMASTAT; MASPIN; NAVELBINE; PACLITAXEL; PREDNISONE; SORAFENIB; SUNITINIB; THALIDOMIDE; THROMBOSPONDIN 1; VANDETANIB; VASCULOTROPIN B; ZOLEDRONIC ACID;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BONE CANCER; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM CELL; HUMAN; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; MACROPHAGE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; STEM CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; BONE NEOPLASMS; DIPHOSPHONATES; ENDOTHELIAL CELLS; HUMANS; IMIDAZOLES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 80455158247     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.113     Document Type: Review

References (68)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285(21), 1182-1186 (1971).
2. Reynolds TY, Rockwell S, Glazer PM. Genetic instability induced by the tumor microenvironment. Cancer Res. 56(24), 5754-5757 (1996). (Pubitemid 26422184)
3. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347), 298-307 (2011).
4. Motzer RJ, Hudes G, Wilding G et al. Phase I trial of sunitinib malate plus interferon a for patients with metastatic renal cell carcinoma. Clin. Genitourin. Cancer 7(1), 28-33 (2009).
5. Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastaticcolorectal cancer: results of a randomized Phase II trial. J. Clin. Oncol. 23(16), 3697-3705 (2005).
6. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004). (Pubitemid 38702844)
7. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88(2), 277-285 (1997). (Pubitemid 28015876)
8. Wang J, Sun Y, Liu Y et al. [Results of randomized, multicenter, double-blind Phase III trial of rh-endostatin (YH 16) in treatment of advanced non-small cell lung cancer patients.]. Zhongguo Fei Ai Za Zhi 8(4), 283-290 (2005). (Pubitemid 41206392)
9. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J. Bone Miner. Res. 9(5), 745-751 (1994). (Pubitemid 24130477)
10. Boissier S, Ferreras M, Peyruchaud O et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 60(11), 2949-2954 (2000). (Pubitemid 30395820)
11. Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J. Bone Miner. Res. 13(11), 1668-1678 (1998). (Pubitemid 28491995)
12. Kavanagh KL, Guo K, Dunford JE et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc. Natl Acad. Sci. USA 103(20), 7829-34 (2006).
13. Senaratne SG, Mansi JL, Colston KW. The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br. J. Cancer 86(9), 1479-86 (2002). (Pubitemid 34548073)
14. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br. J. Cancer 82(8), 1459-68 (2000). (Pubitemid 30175914)
15. Kuroda J, Kimura S, Segawa H et al. p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid. Cancer Sci. 95(2), 186-192 (2004). (Pubitemid 38404322)
16. Romani AA, Desenzani S, Morganti MM, La Monica S, Borghetti AF, Soliani P. Zoledronic acid determines S phase arrest but fails to induce apoptosis in cholangiocarcinoma cells. Biochem. Pharmacol. 78(2), 133-141 (2009).
17. Li YY, Chang JW, Liu YC et al. Zoledronic acid induces cell-cycle prolongation in murine lung cancer cells by perturbing cyclin and Ras expression. Anticancer Drugs 22(1), 89-98
18. Pandha H, Birchall L, Meyer B et al. Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines. J. Urol. 176(5), 2255-2261 (2006). (Pubitemid 44633143)
19. Heikkila P, Teronen O, Moilanen M et al. Bisphosphonates inhibit stromelysin 1 (MMP 3), matrix metalloelastase (MMP 12), collagenase 3 (MMP 13) and enamelysin (MMP 20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 13(3), 245-254 (2002). (Pubitemid 34492706)
20. Derenne S, Amiot M, Barille S et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL 6 and MMP 1 by the tumoral environment. J. Bone Miner. Res. 14(12), 2048-2056 (1999). (Pubitemid 30026954)
21. Santini D, Vincenzi B, Dicuonzo G et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin. Cancer Res. 9(8), 2893-2897 (2003). (Pubitemid 36993246)
22. Wood J, Bonjean K, Ruetz S et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J. Pharmacol. Exp. Ther. 302(3), 1055-1061 (2002). (Pubitemid 34920226)
23. Hasmim M, Bieler G, Ruegg C. Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J. Thromb. Haemost. 5(1), 166-173 (2007). (Pubitemid 44921082)
24. Michailidou M, Brown HK, Lefley DV et al. Microvascular endothelial cell responses in vitro and in vivo: modulation by zoledronic acid and paclitaxel? J. Vasc. Res. 47(6), 481-493 (2010).
25. Bezzi M, Hasmim M, Bieler G, Dormond O, Ruegg C. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J. Biol. Chem 278(44), 43603-43614 (2003). (Pubitemid 37345986)
26. Bellahcene A, Chaplet M, Bonjean K, Castronovo V. Zoledronate inhibits avb3 and avb5 integrin cell surface expression in endothelial cells. Endothelium 14(2), 123-30 (2007). (Pubitemid 47386391)
27. Basi DL, Lee SW, Helfman S, Mariash A, Lunos SA. Accumulation of VEGFR2 in zoledronic acid-treated endothelial cells. Mol. Med. Report 3(3), 399-403 (2010).
28. Li Calzi S, Neu MB, Shaw LC, Kielczewski JL, Moldovan NI, Grant MB. EPCs and pathological angiogenesis: when good cells go bad. Microvasc. Res. 79(3), 207-216
29. Yamada J, Tsuno NH, Kitayama J et al. Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. J. Surg. Res. 151(1), 115-120 (2009).
30. Ziebart T, Pabst A, Klein MO. Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin. Oral Investig. 15(1), 105-111 (2011).
31. Hunt TK, Knighton DR, Thakral KK, Goodson WH 3rd, Andrews WS. Studies on inflammation and wound healing: angiogenesis and collagen synthesis stimulated in vivo by resident and activated wound macrophages. Surgery 96(1), 48-54 (1984). (Pubitemid 14094943)
32. Bergers G, Brekken R, McMahon G et al. Matrix metalloproteinase 9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2(10), 737-744 (2000).
33. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP 9- expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest. 114(5), 623-633 (2004). (Pubitemid 39578752)
34. Ahn GO, Brown JM. Matrix metalloproteinase 9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 13(3), 193-205 (2008). (Pubitemid 351318369)
35. Sato M, Grasser W, Endo N et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest. 88(6), 2095-2105 (1991).
36. Chen T, Berenson J, Vescio R et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J. Clin. Pharmacol. 42(11), 1228-1236 (2002). (Pubitemid 35205058)
37. Dass CR, Choong PF. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol. Cancer Ther. 6(12 Pt. 1), 3263-3270 (2007).
38. Croucher PI, De Hendrik R, Perry MJ et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J. Bone Miner. Res. 18(3), 482-492 (2003). (Pubitemid 36241065)
39. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12(2), 220-229 (1998). (Pubitemid 28108075)
40. Backman U, Svensson A, Christofferson R, H, Azarbayjani F. The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis. Anticancer Res. 28(3A), 1551-1557 (2008). (Pubitemid 351892928)
41. Soltau J, Zirrgiebel U, Esser N et al. Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model. Anticancer Res. 28(2A), 933-941 (2008). (Pubitemid 351578940)
42. Bauerle T, Merz M, Komljenovic D, Zwick S, Semmler W. Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study. Clin. Cancer Res. 16(12), 3215-3225 (2010).
43. Zhang, W, Zhu XD, Sun HC et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin. Cancer Res. 16(13), 3420-3430 (2010).
44. Dirkx AE, Oude Egbrink MG, Wagstaff J, Griffioen AW. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J. Leukoc. Biol. 80(6), 1183-1196 (2006). (Pubitemid 44904956)
45. Aharinejad S, Paulus P, Sioud M et al. Colony-stimulating factor 1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res. 64(15), 5378-5384 (2004). (Pubitemid 39006559)
46. Catena R, Luis-Ravelo D, Anton I et al. PDGFR signaling blockade in marrow stroma impairs lung cancer bone metastasis. Cancer Res. 71(1), 164-174 (2011).
47. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br. J. Cancer 84(8), 1126-1134 (2001). (Pubitemid 32448513)
48. Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J. Natl Cancer Inst. 100(16), 1167-1178 (2008).
49. Karabulut B, Karaca B, Varol U et al. Enhancing cytotoxic and apoptotic effect in OVCAR 3 and MDAH 2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer. J. Exp. Clin. Cancer Res. 29, 102 (2010).
50. Facchini G, Caraglia M, Morabito A et al. Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: Phase I ZANTE trial. Cancer Biol Ther. 10(6), 543-548 (2010).
51. Di Lorenzo G, Autorino R, Perdona S et al. Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a Phase II study. Eur. Urol. 52(4), 1020-1027 (2007). (Pubitemid 47332036)
52. Di Lorenzo G, Autorino R, Giuliano M et al. Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer. Urology 69(2), 347-351 (2007).
53. Scavelli C, Di Pietro G, Cirulli T et al. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol. Cancer Ther. 6(12 Pt. 1), 3256-3262 (2007).
54. Moschetta M, Di Pietro G, Ria R et al. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur. J. Cancer 46(2), 420-429 (2010).
55. Ferretti G, Fabi A, Carlini P et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 69(1), 35-43 (2005). (Pubitemid 41207056)
56. Vincenzi B, Santini D, Dicuonzo G et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J. Interferon Cytokine Res. 25(3), 144-51 (2005). (Pubitemid 40354834)
57. Koch AE, Polverini PJ, Kunkel SL et al. Interleukin 8 as a macrophage-derived mediator of angiogenesis. Science 258(5089), 1798-1801 (1992).
58. Derin D, Soydinc HO, Guney N et al. Serum IL 8 and IL 12 levels in breast cancer. Med. Oncol. 24(2), 163-168 (2007).
59. Papadopoulou E, Tripsianis G, Anagnostopoulos K et al. Significance of serum tumor necrosis factor a and its combination with HER 2 codon 655 polymorphism in the diagnosis and prognosis of breast cancer. Int. J. Biol. Markers 25(3), 126-135 (2010).
60. Santini D, Vincenzi B, Galluzzo S et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin. Cancer Res. 13(15 Pt. 1), 4482-4486 (2007). (Pubitemid 47219717)
61. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases. Med. Oncol. 25(3), 346-349 (2008).
62. Reid IR. Osteonecrosis of the jaw: who gets it, and why? Bone 44(1), 4-10 (2009).
63. Henry DH, Costa L, Goldwasser F et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 29(9), 1125-1132 (2011).
64. Ayllon J, Launay-Vacher V, Medioni J et al. Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? Ann. Oncol. 20(3), 600-601 (2009).
65. Greuter S, Schmid F, Ruhstaller T, Thuerlimann B. Bevacizumab-associated osteonecrosis of the jaw. Ann. Oncol. 19(12), 2091-2092 (2008).
66. Sarasquete ME, Garcia-Sanz R, Marin L et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 112(7), 2709-2712 (2008).
67. Michaelis UR, Fisslthaler B, Barbosa-Sicard E, Falck J, Fleming R, Busse R. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J. Cell Sci. 118(Pt 23), 5489-5498 (2005). (Pubitemid 43079290)
68. Freiberger JJ. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J. Oral Maxillofac. Surg. 67(Suppl. 5), 96-106 (2009).